ProPhase and ABL Enter Reverse Merger LOI Valuing ProPhase at $30 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 19 2025
0mins
Should l Buy ?
Source: Newsfilter
- Transaction Intent: ProPhase Labs and ABL have signed a non-binding Letter of Intent for a reverse merger, aiming to make ABL the majority owner of the combined entity, which is expected to deliver near-term value and long-term growth for ProPhase shareholders.
- Cash Dividend: ProPhase may declare a special cash dividend of up to $10 million for shareholders, designed to provide a differentiated value pathway independent of the future performance of the merged company.
- Asset Carve-Out: All Crown Medical Collections receivables are expected to be carved out for the exclusive benefit of current ProPhase shareholders, with anticipated collections of approximately $50 million net, enhancing shareholder value.
- Strategic Integration: Post-merger, ABL shareholders are expected to own about 76% of the combined company, with ProPhase's Nebula Genomics platform and BE-Smart Esophageal Cancer Test being operated by a newly established U.S. subsidiary, facilitating focused capital allocation and strategic execution.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
